Lack of consideration of sex and gender in COVID-19 clinical studies.
Nat Commun
; 12(1): 4015, 2021 07 06.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1298840
ABSTRACT
Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Estudos Clínicos como Assunto
/
COVID-19
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Tópicos:
Vacinas
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Nat Commun
Assunto da revista:
Biologia
/
Ciência
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
S41467-021-24265-8
Similares
MEDLINE
...
LILACS
LIS